Jade Biosciences appoints Brad Dahms as new CFO

SAN FRANCISCO - Jade Biosciences, Inc. (NASDAQ:JBIO), a biotechnology company with a market capitalization of $322 million, has appointed Brad Dahms as Chief Financial Officer, the autoimmune disease-focused company announced Tuesday. According to InvestingPro analysis, the company maintains a strong financial health score, despite currently trading above its Fair Value.

Dahms joins Jade with experience from previous CFO roles at several biotechnology companies. Most recently, he served as Chief Financial Officer and Chief Business Officer at IDRx, where he oversaw its sale to GSK for up to $1.15 billion. His prior positions include CFO at Theseus Pharmaceuticals, where he led the company’s initial public offering and subsequent sale to Concentra Biosciences, and CFO at Selecta Biosciences. He inherits a company with strong liquidity, as evidenced by a current ratio of 5.81 and liquid assets exceeding short-term obligations.

"Brad is a proven strategic and financial leader with a strong track record guiding biotech companies through multiple phases of growth," said Tom Frohlich, Chief Executive Officer of Jade Biosciences, in a press release statement.

Jade Biosciences is developing therapies for autoimmune diseases, with its lead candidate JADE101 targeting the cytokine APRIL for treating immunoglobulin A nephropathy. The company expects to initiate its first human clinical trial for JADE101 in the second half of 2025.

The appointment follows Jade’s recent Nasdaq listing and private financing round. The company’s pipeline also includes a second development candidate, JADE201, and an antibody discovery program currently in preclinical development.

Dahms, who began his career in healthcare investment banking with roles at Cantor Fitzgerald, RBC Capital Markets, and J.P. Morgan, holds a B.S. in Economics from The Ohio State University. With the company’s next earnings report scheduled for August 11, 2025, analysts maintain a strong buy consensus with price targets ranging from $14 to $19. For more detailed financial metrics and exclusive insights, visit InvestingPro, which offers additional ProTips and comprehensive analysis tools.

In other recent news, Jade Biosciences has been at the center of several significant developments. The company recently completed a merger with Aerovate Therapeutics, which included a 1-for-35 reverse stock split approved by Aerovate’s board. This merger is expected to result in the new combined entity trading under the ticker "JBIO" on Nasdaq. In conjunction with the merger, Aerovate announced a special cash dividend of $69.6 million, or approximately $2.40 per share, to its stockholders.

Guggenheim has upgraded Jade Biosciences’ stock rating from Neutral to Buy, citing the company’s transformation following the merger and its promising drug candidate, JADE-101. Stifel also initiated coverage of Jade Biosciences with a Buy rating, setting a price target of $19.00, driven by the potential of its lead product candidate, JADE-001, in treating IgA nephropathy. TD Cowen followed suit, assigning a Buy rating based on JADE-001’s unique advantages and significant market potential in the IgAN therapy sector. These recent developments highlight a period of strategic growth and optimism for Jade Biosciences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.